ES2505890T3 - Conjugados que comprenden nanopartículas recubiertas con compuestos que contienen platino - Google Patents

Conjugados que comprenden nanopartículas recubiertas con compuestos que contienen platino Download PDF

Info

Publication number
ES2505890T3
ES2505890T3 ES09768395.7T ES09768395T ES2505890T3 ES 2505890 T3 ES2505890 T3 ES 2505890T3 ES 09768395 T ES09768395 T ES 09768395T ES 2505890 T3 ES2505890 T3 ES 2505890T3
Authority
ES
Spain
Prior art keywords
formula
conjugate
platinum
linker
iii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09768395.7T
Other languages
English (en)
Spanish (es)
Inventor
Víctor FRANCO PUNTES
Fernando DOMÍNGUEZ PUENTE
Francisco Manuel ROMERO MARTÍNEZ
Óscar GALLEGO RUBIO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Santiago de Compostela
Institució Catalana de Recerca i Estudis Avançats
Institut Català de Nanociència i Nanotecnologia
University of Valencia
Fundacio Institut de Recerca de lHospital de La Santa Creu i Sant Pau
Original Assignee
University of Santiago de Compostela
Institució Catalana de Recerca i Estudis Avançats
Institut Català de Nanociència i Nanotecnologia
University of Valencia
Fundacio Institut de Recerca de lHospital de La Santa Creu i Sant Pau
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Santiago de Compostela, Institució Catalana de Recerca i Estudis Avançats, Institut Català de Nanociència i Nanotecnologia, University of Valencia, Fundacio Institut de Recerca de lHospital de La Santa Creu i Sant Pau filed Critical University of Santiago de Compostela
Application granted granted Critical
Publication of ES2505890T3 publication Critical patent/ES2505890T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Ceramic Engineering (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Powder Metallurgy (AREA)
ES09768395.7T 2008-12-16 2009-12-15 Conjugados que comprenden nanopartículas recubiertas con compuestos que contienen platino Active ES2505890T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08171870 2008-12-16
EP08171870 2008-12-16
PCT/EP2009/067136 WO2010069941A1 (en) 2008-12-16 2009-12-15 Conjugates comprising nanoparticles coated with platinum containing compounds

Publications (1)

Publication Number Publication Date
ES2505890T3 true ES2505890T3 (es) 2014-10-10

Family

ID=40568646

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09768395.7T Active ES2505890T3 (es) 2008-12-16 2009-12-15 Conjugados que comprenden nanopartículas recubiertas con compuestos que contienen platino

Country Status (13)

Country Link
US (1) US9023370B2 (enExample)
EP (1) EP2379114B1 (enExample)
JP (1) JP5873719B2 (enExample)
CA (1) CA2745972C (enExample)
CY (1) CY1115601T1 (enExample)
DK (1) DK2379114T3 (enExample)
ES (1) ES2505890T3 (enExample)
HR (1) HRP20140804T1 (enExample)
IL (1) IL213408A (enExample)
PL (1) PL2379114T3 (enExample)
PT (1) PT2379114E (enExample)
SI (1) SI2379114T1 (enExample)
WO (1) WO2010069941A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0909435D0 (en) * 2009-06-02 2009-07-15 Univ Strathclyde Nanoparticle for biomolecule delivery
ES2392528B1 (es) * 2010-12-28 2013-10-21 Endor Nanotechnologies, S.L. Sistema de liberación de agente terapéutico, composiciones farmacéuticas que lo contienen, su preparación y su uso médico.
ITRM20130138A1 (it) 2013-03-07 2014-09-08 Consiglio Nazionale Ricerche Assemblato comprendente un assorbitore della luce nel vicino infrarosso legato covalentemente ad un inibitore dell'anidrasi carbonica
JP6316011B2 (ja) * 2014-02-04 2018-04-25 国立大学法人滋賀医科大学 抗癌剤が担持されたナノ粒子
JP7018191B2 (ja) * 2016-01-29 2022-02-10 国立大学法人北海道大学 細胞内物質移送システムおよびその利用
PL236093B1 (pl) 2017-07-04 2020-11-30 Dominika Szczepaniak Rozpuszczalne w wodzie kompleksy złota (III), sposób wytwarzania rozpuszczalnych w wodzie kompleksów złota (III) i ich zastosowanie
EP3908324B1 (en) 2019-01-08 2022-05-11 Nanonica S.A. Conjugates comprising nanoparticles coated with platinum derivatives through sulfonyl or phosphonyl-containing linkers
TW202615847A (zh) * 2024-09-27 2026-04-16 高雄醫學大學 檢測ｄｎａ甲基化的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR851932B (enExample) 1984-08-14 1985-12-13 Engelhard Corp
JP2866554B2 (ja) 1992-08-25 1999-03-08 松下電器産業株式会社 情報記録媒体とその製造方法及び情報記録媒体の使用方法
JP2005535604A (ja) 2002-06-03 2005-11-24 アルニス バイオサイエンシーズ， インコーポレイテッド 治療剤を含むポリマーナノ物品
WO2006037081A2 (en) * 2004-09-28 2006-04-06 The Regents Of The University Of California Nanoparticle radiosensitizers
US7601331B2 (en) * 2004-11-10 2009-10-13 National University Of Singapore NIR-sensitive nanoparticle
US20060222595A1 (en) * 2005-03-31 2006-10-05 Priyabrata Mukherjee Nanoparticles for therapeutic and diagnostic applications
US8785505B2 (en) * 2005-10-28 2014-07-22 The Regents Of The University Of California Toxicology and cellular effect of manufactured nanomaterials

Also Published As

Publication number Publication date
WO2010069941A1 (en) 2010-06-24
US20110262500A1 (en) 2011-10-27
CY1115601T1 (el) 2017-01-04
CA2745972A1 (en) 2010-06-24
PT2379114E (pt) 2014-10-06
IL213408A0 (en) 2011-07-31
HRP20140804T1 (hr) 2014-11-07
SI2379114T1 (sl) 2014-11-28
JP2012512149A (ja) 2012-05-31
IL213408A (en) 2017-06-29
US9023370B2 (en) 2015-05-05
EP2379114A1 (en) 2011-10-26
JP5873719B2 (ja) 2016-03-01
PL2379114T3 (pl) 2014-12-31
CA2745972C (en) 2016-11-01
EP2379114B1 (en) 2014-07-09
DK2379114T3 (da) 2014-09-29

Similar Documents

Publication Publication Date Title
Li et al. Ultrasmall MoS2 nanodots-doped biodegradable SiO2 nanoparticles for clearable FL/CT/MSOT imaging-guided PTT/PDT combination tumor therapy
Zhou et al. Nanomaterials for cancer therapies
Ma et al. Inorganic nanocarriers for platinum drug delivery
Zheng et al. A continuous stimuli-responsive system for NIR-II fluorescence/photoacoustic imaging guided photothermal/gas synergistic therapy
Zhou et al. Hyaluronic acid-functionalized hollow mesoporous silica nanoparticles as pH-sensitive nanocarriers for cancer chemo-photodynamic therapy
Wang Synthetic methods of CuS nanoparticles and their applications for imaging and cancer therapy
Khan et al. Gold nanoparticles: synthesis and applications in drug delivery.
Fang et al. Albumin-MnO2 gated hollow mesoporous silica nanosystem for modulating tumor hypoxia and synergetic therapy of cervical carcinoma
Verma et al. Development of surface functionalized hydroxyapatite nanoparticles for enhanced specificity towards tumor cells
Bose et al. Cyclodextrin nanoparticles in targeted cancer theranostics
Singh et al. Biosynthesis of folic acid appended PHBV modified copper oxide nanorods for pH sensitive drug release in targeted breast cancer therapy
EP2379114B1 (en) Conjugates comprising nanoparticles coated with platinum containing compounds
Bai et al. Graphene-based drug delivery systems
Sironmani et al. Silver nanoparticles–universal multifunctional nanoparticles for bio sensing, imaging for diagnostics and targeted drug delivery for therapeutic applications
Zeb et al. Recent progress and drug delivery applications of surface-functionalized inorganic nanoparticles in cancer therapy
Santos et al. Inorganic nanoparticles in targeted drug delivery and imaging
Zhang et al. Functionalized MoS2-erlotinib produces hyperthermia under NIR
Pal et al. NIR-responsive 5-Fluorouracil delivery using polydopamine coated polygonal CuS nanoplates for synergistic chemo-photothermal therapy on breast cancer
Wang et al. Hybrid micelles loaded with chemotherapeutic drug-photothermal agent realizing chemo-photothermal synergistic cancer therapy
Guo et al. Biomimetic nanotherapeutics based on oxygen supply and ultrasmall Cu-Se-Au alloy nanoparticles for boosting radio-photothermal ablation of breast cancer
CN104491868A (zh) 新型基于抗体偶联化疗药物纳米adc及制备方法和应用
Kumar et al. Overview of inorganic nanoparticles: An expanding horizon in tumor therapeutics
He et al. Targeted gold nanoparticles for ovarian cancer
Li et al. Tumor microenvironment-responsive cerium oxide nanozyme coated ZIF-8 nanoplatform with ICG encapsulation for precise breast cancer surgery and efficacious synergistic suppression
Zayed et al. Effect of Chemical Binding of Doxorubicin Hydrochloride to Gold Nanoparticles, Versus Electrostatic Adsorption, on the In Vitro Drug Release and Cytotoxicity to Breast Cancer Cells: Zayed et al.